

1

Article Title

First Author^{1,*}, **Co-Author**² and **Co-Author**²

¹Laboratory X, Institute X, Department X, Organization X, City X, State XX (only USA, Canada and Australia), Country X

²Laboratory X, Institute X, Department X, Organization X, City X, State XX (only USA, Canada and Australia), Country X

Correspondence*:

Corresponding Author

Laboratory X, Institute X, Department X, Organization X, Street X, City X, State XX (only USA, Canada and Australia), Zip Code, X Country X, email@uni.edu

2 ABSTRACT

3 For full guidelines regarding your manuscript please refer to Author Guidelines
4 or **Table 1** for a summary according to article type.

5 **Keywords:** Text Text Text Text Text Text Text Text

1 INTRODUCTION

6 Text
7 Text. Text
8 Text. Text
9 Text. Text
10 Text.

2 MATERIAL & METHODS

11 Text Text Text Text Text Text Text Text Text Text Text Name et al. (1996) Text Text Text Text Text Text
12 Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text. Surname1 (2010) might want to
13 know about text text text text Text Text Text Text Text Text Text Text Text Text Text Text. (LastName1
14 et al., 2013) might want to know about text text text text Text Text Text Text Text Text Text Text Text Text
15 Text
16 Text Text. Name (1993) might want to know about text text text text Surname (2002)

17 Please note that large tables covering several pages cannot be included in the final PDF for formatting
18 reasons. These tables will be published as supplementary material on the online article abstract page at the
19 time of acceptance. The author will notified during the typesetting of the final article if this is the case. A
20 link in the final PDF will direct to the online material.

21 2.1 Original Research Articles, Clinical Trial Articles, and Technology Reports

22 For Original Research Articles, Clinical Trial Articles, and Technology Reports the section headings
23 should be those appropriate for your field and the research itself. It is recommended to organize your
24 manuscript in the following sections or their equivalents for your field:

Table 1. Maximum size of the Manuscript

	Abstract max. length (incl. spaces)	Figures or tables	Manuscript max. length
Clinical Case Study Clinical Trial Hypothesis and Theory Methods Original Research Review Technology Report	2000 characters	15	12000 words
Focused Review	2000 characters	5	5000 words
CPC	1250 characters	6	2500 words
Perspective Mini Review	1250 characters	2	3000 words
Data Report	None	2	3000 words
Classification	1250 characters	10	2000 words
Editorial	None	None	1000 words
Frontiers Commentary General Commentary Book review	None	1	1000 words
Opinion Specialty Grand Challenge Field Grand Challenge	None	1	2000 words

- 25 • Introduction: Succinct, with no subheadings.
- 26 • Materials and Methods: This section may be divided by subheadings. This section should contain
- 27 sufficient detail so that when read in conjunction with cited references, all procedures can be repeated.
- 28 • Results: This section may be divided by subheadings. Footnotes should not be used and have to be
- 29 transferred into the main text.
- 30 • Discussion: This section may be divided by subheadings. Discussions should cover the key findings
- 31 of the study: discuss any prior art related to the subject so to place the novelty of the discovery in
- 32 the appropriate context; discuss the potential short-comings and limitations on their interpretations;
- 33 discuss their integration into the current understanding of the problem and how this advances the
- 34 current views; speculate on the future direction of the research and freely postulate theories that could
- 35 be tested in the future.

36 Please note that the Material and Methods section can be placed in any of the following ways: before

37 Results, before Discussion or after Discussion.

38 2.2 Clinical Case Studies

39 For Clinical Case Studies the following sections are mandatory:

- 40 • Introduction: Include symptoms at presentation, physical exams and lab results.

Table 2. Resolution Requirements for the figures

Image Type	Description	Format	Color Mode	Resolution
Line Art	An image composed of lines and text, which does not contain tonal or shaded areas.	TIFF, JPEG	RGB, Bitmap	900 - 1200 dpi
Halftone	A continuous tone photograph, which contains no text.	TIFF, EPS, JPEG	RGB, Grayscale	300 dpi
Combination	Image contains halftone + text or line art elements.	TIFF, JPEG	RGB, Grayscale	600 - 900 dpi

- Background: This section may be divided by subheadings. Include history and review of similar cases.
- Results: This section may be divided by subheadings. Include diagnosis and treatment.
- Concluding Remarks

3 RESULTS

3.1 Figures

Frontiers requires figures to be submitted individually, in the same order as they are referred to in the manuscript. Figures will then be automatically embedded at the bottom of the submitted manuscript. Kindly ensure that each table and figure is mentioned in the text and in numerical order. Permission must be obtained for use of copyrighted material from other sources (including the web). Please note that it is compulsory to follow figure instructions. Figures which are not according to the guidelines will cause substantial delay during the production process.

Table 2 shows the resolution requirements for the figures. The figures must be legible:

1. The smallest visible text is no less than 8 points in height, when viewed at actual size.
2. Solid lines are not broken up.
3. Image areas are not pixelated or stair stepped.
4. Text is legible and of high quality.
5. Any lines in the graphic are no smaller than 2 points width.
6. The actual size of the figure must be of at least 8.5 cm.

3.2 Nomenclature

- The use of abbreviations should be kept to a minimum. Non-standard abbreviations should be avoided unless they appear at least four times, and defined upon first use in the main text. Consider also giving a list of non-standard abbreviations at the end, immediately before the Acknowledgments.
- Gene symbols should be italicized; protein products are not italicized.
- Chemical compounds and biomolecules should be referred to using systematic nomenclature, preferably using the recommendations by IUPAC.
- We encourage the use of Standard International Units in all manuscripts.
- To take part in the Resource Identification Initiative, please cite antibodies, genetically modified organisms, software tools, data, databases and services using the corresponding catalog number and RRID in your current manuscript. For more information about the project and for steps on how to search for an RRID, please click here.

$$\sum x + y = Z \quad (1)$$

4 DISCUSSION

70 Text
71 Text Text Text Text. Additional Requirements:

72 4.1 Corrections

73 If you need to communicate important changes to a published article please submit a General Commentary.
74 Submit the article with the title Corrigendum: Original Title of Article.

75 **4.2 Commentaries on Articles**

At the beginning of your Commentary, please provide the citation of the article commented on. Rebuttals may be submitted in response to Commentaries; our limit in place is one commentary and one response. Rebuttals should also be submitted as General Commentary articles.

79 **4.3 Human Search and Animal Research**

80 All experiments on live vertebrates or higher invertebrates must be performed in accordance with relevant
81 institutional and national guidelines and regulations. In the manuscript, authors must identify the committee
82 approving the experiments and must confirm that all experiments conform to the relevant regulatory
83 standards. For manuscripts reporting experiments on human subjects, authors must identify the committee
84 approving the experiments and must also include a statement confirming that informed consent was
85 obtained from all subjects. In Original Research Articles and Clinical Trial Articles these statements should
86 appear in the Materials and Methods section.

87 4.4 Clinical Trial Registration

88 Clinical trials should be registered in a public trials registry in order to become the object of a publication
89 at Frontiers. Trials must be registered at or before the start of patient enrollment. A clinical trial is defined
90 as "any research study that prospectively assigns human participants or groups of humans to one or more
91 health-related interventions to evaluate the effects on health outcomes."(www.who.int/ictpr/en). A list of
92 acceptable registries can be found at www.who.int/ictpr/en and www.icmje.org.

93 4.5 Inclusion of Proteomics Data

94 Authors should provide relevant information relating to how the peptide/protein matches were undertaken.
95 including methods used to process and analyze data, false discovery rates (FDR) for large-scale studies
96 and threshold or cut-off rates for peptide and protein matches. Further information could include software
97 used, mass spectrometer type, sequence database and version, number of sequences in database, processing
98 methods, mass tolerances used for matching, variable/fixed modifications, allowable missed cleavages, etc.

99 Authors should provide as supplementary material information used to identify proteins and/or peptides.
100 This should include information such as accession numbers, observed mass (m/z), charge, delta mass,
101 matched mass, peptide/protein scores, peptide modification, miscleavages, peptide sequence, match rank,
102 matched species (for cross species matching), number of peptide matches, ambiguous protein/peptide
103 matches should be indicated, etc. For quantitative proteomics analyses authors should provide information

For peptide matches with biologically relevant post-translational modifications (PTM) and for any protein match that has occurred using a single mass spectrum, authors should include this information as raw data, annotated spectra or submit data to an online repository (recommended option). Authors are encouraged to submit raw or matched data and 2-DE images to public proteomics repositories. Submission codes and/or links to data should be provided within the manuscript.

Frontiers supports the policy of data sharing, and authors are advised to make freely available any materials and information described in their article, and any data relevant to the article (while not compromising confidentiality in the context of human-subject research) that may be reasonably requested by others for the purpose of academic and non-commercial research. In regards to deposition of data and data sharing through databases, Frontiers urges authors to comply with the current best practices within their discipline.

117 The authors declare that the research was conducted in the absence of any commercial or financial
118 relationships that could be construed as a potential conflict of interest.

The statement about the authors and contributors can be up to several sentences long, describing the tasks of individual authors referred to by their initials and should be included at the end of the manuscript before the References section.

122 Text
123 Text Text Text Text Text. Text Text Text Text Text Text Text Text Text Text Text Text Text Text Text
124 Text Text Text Text Text Text Text Text Text Text Text.

SUPPLEMENTAL DATA

[illegible]

131 LastName1, A., LastName2, A., and LastName2, A. (2013). Article title. *Frontiers in Neuroscience* 30,
132 10127–10134. doi:10.3389/fnins.2013.12345

- 133 Name, A. (1993). *The title of the work* (The city: The name of the publisher)
- 134 Name, C., Surname, D., and LastName, F. (1996). The title of the work. In *The title of the conference*
135 *proceedings*, eds. E. Name1 and E. Name2 (The name of the publisher), 41–50
- 136 Surname, B. (2002). The title of the work. In *The title of the book*, ed. E. Name (The city: The name of the
137 publisher). 201–213
- 138 Surname1, H. (2010). *The title of the work* (Patent country: Patent number)

FIGURES